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Salivary gland tumors account for almost 5% of head and neck malignancies.1 Mucoepidermoid carcinoma (MEC) was first described by Stewart 
et al in 1945 as a separate entity in salivary gland neo-
plasms.2  The prevalence of MEC among salivary gland 
tumors reported in Pakistan is around 9.5% to 25.6%3 
and is considered to be the most common malignancy 
of major and minor salivary glands, with an overall 
prevalence of 12% to 40% worldwide.4 It is thought to 
arise from the reserve cells in the excretory ducts of the 
salivary glands and consists of mucous, epidermoid and 
intermediate cells.5 MEC carries a slight female pre-
ponderance with a female-to-male ratio of around 3:2.6 
MEC has a predilection for adults in their fourth to 
sixth decade with the highest prevalence noted during 
the fifth decade of life.2,6 
Differentiation of MEC into low grade, intermedi-
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BaCKgROunD anD OBjECtIVES: mucoepidermoid carcinoma is the most common salivary gland tumor 
with varying behavior among different histopathological grades. the objective of this study was to determine 
the expression of Bcl-2 protein in mucoepidermoid carcinoma (mEC) and to correlate with histological grades.
mEthODS: the records of 40 cases of mEC were collected from the histopathology department. fresh slides 
were prepared and fresh diagnoses were made using the grading criteria for mEC. immunohistochemical mark-
ers for Bcl-2 were applied and the results analyzed using the chi-square test.
RESuLtS: of 40 cases, 20 were males and 20 were females. the range in age of the patients was 6 to 67 years 
mean (sD) was 42.6 (1.85) years. twenty-two were low grade (55%), 11 high grade (27.5%) and 7 (17.5%) were 
intermediate grade mEC. among these 40 cases, Bcl-2 expression was positive in 24 cases and negative in 16 
cases. in 22 cases of low-grade mEC, 19 were positive while only 3 were negative. in high-grade tumors, all 11 
cases were found to have a negative expression of Bcl-2 protein. in intermediate-grade mEC, 5 cases showed 
positive expression while only 2 cases showed negative expression.
COnCLuSIOn: Bcl-2 protein expression showed positive expression in low-grade and negative expression in 
high-grade mEC. intermediate grade showed more than 50% positive results for Bcl-2. Correlation between 
grades of mEC and expression of Bcl-2 is statistically significant and can be used for the depicting the prognosis 
of mEC along with other prognostic and clinico-pathological parameters.
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ate grade and high grade is at times difficult especially 
the differentiation between intermediate grade and high 
grade and between high-grade MEC and poorly differ-
entiated squamous cell carcinoma. Histopathological 
grading is an important prognostic factor regarding 
5-year survival outcome (92%-100% in low grade, 62%-
93% in intermediate grade and 0%-43% in high grade)7 
and this diagnosis as well as prediction of prognosis 
can be facilitated by immunohistochemistry. Bcl-2 has 
emerged as a marker with a strong potential to forecast 
and predict the behavior of MEC by indicating its pro-
liferative capacity.8      
Bcl-2 derives its name from B-cell lymphoma-2, as 
it is the second member of range of proteins initially 
described on chromosomes 14 and 18 in follicular lym-
phomas. It governs mitochondrial outer membrane 
permeabilization and can be either pro-apoptotic or 
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anti-apoptotic. Expression of Bcl-2 is more common 
with low-grade MEC than intermediate- or high-grade 
MEC and this expression correlates with less tumor ag-
gression, higher survival rates and better prognosis so 
it can be a useful prognostic marker for depicting the 
behavior of MEC.7,9 Bcl-2 is a proto-oncogene found in 
the endoplasmic reticulum, nuclear envelope and mi-
tochondrial membrane. It was named after B-cell lym-
phoma-2, as it is the second member of range of pro-
teins initially described on chromosomes 14 and 18 in 
follicular lymphomas.19 It governs mitochondrial outer 
membrane permeabilization and can be either pro-
apoptotic or anti-apoptotic. It is found to suppress the 
growth of lymphocytes and leukemic cells by inhibiting 
the cell function in follicular B-cell lymphoma.
The aim of the current study was to determine the 
expression of immunohistochemical marker Bcl-2 pro-
tein in the different grades of MEC for predicting the 
aggressiveness and behavior of this tumor in our pop-
ulation. The rationale for the study was that if we are 
able to depict the aggressiveness of MEC, the treating 
surgeon may be able to treat a primary tumor in a more 
radical fashion and hence decrease the chances of recur-
rence and distant metastasis, thus improving survival 
rates for patients having MEC.
mEthODS
Forty diagnosed cases of MEC were retrieved from 
the files of the institution along with their paraffin-
embedded blocks. The data on age, gender, size and site 
of primary tumor was extracted from clinical histories 
presented with each case. Histopathological grading 
was re-assessed on the samples after viewing them un-
der the microscope. Grading was done on the basis of 
the grading system described by Auclair et al,10 which 
divides MEC into low (0-4 points), intermediate (5-6 
points) and high (7-14 points) grades. These points 
were assigned on the basis of five histopathological fea-
tures, which are the intracystic component, neural inva-
sion, necrosis, mitosis and anaplasia. Necrosed, scanty 
and autolysed tissue samples were excluded as applica-
tion of the immunohistochemical marker was difficult 
and uncertain in such cases.
After grading of the tumor samples, immunohisto-
chemical marker Bcl-2 (Vision Biosystems, Novocastra, 
United Kingdom) was applied. For Bcl-2 protein ex-
pression, we followed the scoring system used by Kroger 
et al.11 According to this system, intensity (I) and per-
centage (P) of cytoplasmic staining was calculated. I was 
graded as 0, +1, +2 and +3 where 0 was no staining, +1 
was mild, +2 was moderate and +3 was strong staining. 
Similarly P was graded on a scale of 0-4, where 0 was 0% 
cytoplasmic staining, 1 was <10%, 2 was 10-50%, 3 was 
51-80% and 4 was >80%. The total score was calculated 
by multiplying I by P. Total score of < 4 was taken as 
negative and > 4 was taken as positive. This score was 
then co-related with the tumor grade.  
The data was collected on a specially designed 
Performa, in the form of variables and was analyzed 
using SPSS version 17.0 (IBM Corp, Armonk, New 
York, United States). Descriptive statistics were used 
to describe the data. The mean and standard devia-
tion were calculated for age and frequency for gender 
and site of malignancy. The chi-square test was used to 
compare histological grades with expression of immune 
marker Bcl-2. A P value <.05 was considered statisti-
cally significant.
RESuLtS 
The age range of patients was from 6 to 67 years with 
a mean (SD) of 42.6 (1.9) years. Twenty were males 
and 20 were females with a male to female ratio of 1:1. 
Of 40 cases, 23 (57.5%) occurred in the parotid gland, 
3 (7.5%) in the submandibular gland and 14 (35%) 
in minor salivary glands. The grade in 22 was low-
grade MEC, showing the highest proportion (55%), 
whereas high-grade MEC comprised 27.5% of the to-
tal tumors being 11 in number out of the total of 40. 
Intermediate-grade MEC showed the lowest percent-
age of 17.5%, and only 7 cases were found to be of in-
termediate grade (Figure 1).
Intensity of cytoplasmic staining of Bcl-2 showed that 
20 cases of 22 low grade MEC showed moderate inten-
Figure 1.  distribution of histopathological grades of 
mucoepidermoid carcinoma.
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Table 1. intensity staining of Bcl-2 by grades.
  Grade
Intensity of Bcl-2 (I)
None Low Moderate Total
  low grade 0 2 22 22
  intermediate grade 0 2 5 7
  High grade 1 9 1 11
  Total 1 13 26 40
Table 2. percentage of Bcl-2 staining by grade.
  Grade
Percentage of staining (P)
<10% 10-50% 51-80% >80% Total
  low grade 0 3 12 7 22
  intermediate grade 0 2 1 4 7
  High grade 3 5 3 0 11
  Total 3 10 16 11 40
Table 3. Overall expression of Bcl-2 with grades.
  Grade
Overall expression of Bcl-2
Positive Negative Total
  low grade 19 3 22
  intermediate grade 5 2 7
  High grade 0 11 11
  Total 24 16 40
sity and the remaining two showed low intensity. In high-
grade tumors, 9 of the 11 showed low or mild intensity 
whereas one case showed moderate intensity while the 
remaining one case showed no intensity of Bcl-2 stain-
ing. Tumors showing intermediate grade presented with 
moderate intensity in 5 cases whereas the rest of the 2 
cases showed low or mild intensity (Table 1).
For the percentage of staining of Bcl-2 in the 22 cas-
es of low grade tumors, 12 showed 51% to 80% (score 
3 points) while 7 cases showed > 80% (score 4 points) 
and only 3 cases showed 10-50% (score 2 points). In 
high-grade tumors the percentage of staining was 10% 
to 50% (score 2 points) in 5 cases while 3 cases showed 
a percentage of stained cells to be 51% to 80% (score 
3 points) and the remaining 3 showed <10% staining 
(score 1 point). In intermediate grade, 4 cases showed 
>80% staining (score 4 points), 1 case showed 51% to 
80% staining (score 3 points) and 2 cases showed 10% 
to 50% staining (score 2 points) (Table 2).
In overall score, it was observed that 24 cases 
showed positive expression and 16 cases showed 
negative expression. In 22 cases of low-grade MEC, 
19 were positive and 3 were negative. In high-grade 
tumors, all the 11 cases showed a negative expression 
of Bcl-2 protein. In intermediate-grade MEC, 5 cases 
showed positive expression while only 2 cases showed 
negative expression (Table 3). When the chi square 
test was applied the results were found to be statisti-
cally significant (P<.05).
DISCuSSIOn
Salivary gland neoplasms comprise of 1% to 4% of all 
body tumors.12 MEC is the commonest of all salivary 
gland malignancies accounting for approximately 10% 
to 15% of salivary tumors.13 This tumor has been ob-
served and documented in major and minor salivary 
glands of both children and adults. It is a unique epi-
thelial neoplasm composed of epidermoid, mucous 
and intermediate cells.5,12,13 The clinical behavior of 
an MEC is strongly dependent upon its histological 
grade, varying from a relatively low grade neoplasm to 
an extremely aggressive tumor showing high mortal-
ity. Studies have proved that the histological grade of 
an MEC is a predictor of prognosis and also affects the 
treatment protocol for patients.10,14,15
We observed that there was no predilection of MEC 
for any gender (male to female ratio of 1:1). This fact 
is in accordance with that reported by Nance et al6 and 
Brandwein et al14 whereas Qureshi et al,2 Okabe et al16 
and Rahman et al4 reported a female predilection. On 
the contrary, a study by Rapidis et al13 showed a male 
preponderance. We observed that the most common-
ly involved gland was the parotid gland (57.5%). The 
next most common location was minor salivary glands 
(35%). This finding is similar to studies by Qureshi et 
al2, Brandwein et al14 and Rapidis et al.13 However, Pires 
et al,7 Tian et al17 and Kokemueller et al18 reported that 
minor salivary glands were the most common location 
for MEC in their respective groups followed by the pa-
rotid gland as the second most common site.
Of the 40 cases in our study, 22 were diagnosed as 
low-grade MEC (55%), 11 cases were reported as high-
grade (28%), while the remaining 7 cases showed fea-
tures of intermediate MEC (17%). We conclude that 
most of MEC found in our population are of low grade. 
These results are in accordance with that reported by 
Pires et al,7 Rapidis et al13 and Kokemuller et al.18
In our study, overall Bcl-2 expression was found to 
be positive in 60% of cases and negative in 40%. In cases 
of low-grade MEC, 86% of cases showed positive ex-
pression, while only 14% were negative. In high-grade 
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tumors, all cases were negative while in intermediate 
grade MEC, 71% cases were positive and only 29% 
showed negative expression of Bcl-2. These findings 
suggest that expression of Bcl-2 is more common in low 
grade MEC than intermediate- or high-grade MEC 
and its positivity correlates with less aggressiveness of 
the tumor, higher survival rates and better prognosis so 
it can be a useful prognostic marker for depicting the 
behavior of MEC. 
The results of the present study are in accordance 
with other studies. Pires et al7, Zyada et al9 and Yin et 
al20 applied Bcl-2 protein on MEC in their study and 
found almost similar results and concluded that posi-
tivity of Bcl-2 correlates with a favorable prognosis and 
consequently a higher survival outcome. On the other 
hand, a very recent study undertaken by Manjunatha et 
al21 on expression of Bcl-2 in benign and malignant sali-
vary glands suggested greater expression of Bcl-2 in ma-
lignant salivary gland tumors and it correlates with high 
survival rate of tumor cells suggesting a poor prognosis. 
In the current study, we used the scoring criteria 
described by Kroger et al11, in year 2006, to determine 
prognostic and predictive effect of immunohistochemi-
cal factors in high-risk primary breast cancer patients. 
Using this criterion we derived statistically significant 
results between expression of Bcl-2 and grades of 
MEC. Very few studies have been carried out on the 
expression of Bcl-2 in MEC and its correlation with the 
grade of MEC. The present study signifies that expres-
sion of Bcl-2 is strongly related to the grade of tumor in 
MEC of salivary glands. Bcl-2 can be a potential prog-
nostic indicator for MEC and it can help in evaluating 
the grade of tumor and its aggressiveness especially in 
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the case of intermediate-grade tumors. One limitation 
of the study was that there is no 5-year follow up and 
the reason for that is that it was not possible to contact 
all the patients as contact details were not available.
In our setting, low-grade MEC is the most common 
grade among the three grades of MEC. Expression of 
Bcl-2 is found positive in all the low grades of MEC 
and negative in all the high grades. While in interme-
diate grade, more than 50% showed positive results. 
Bcl-2 expression correlates with low grade and good 
prognosis. Correlation of Bcl-2 expression in MEC is 
statistically significant, displaying a positive association. 
Intermediate grade had variable results, but more than 
50% displayed higher positivity of Bcl-2 suggesting a 
better prognosis for these tumors.
The results of this study recommend that expression 
of Bcl-2 may be included in the criteria used for grading 
of MEC. Bcl-2, along with other prognostic and clini-
copathological markers can help in predicting the ag-
gressiveness and prognosis of the tumor. This can help 
in guiding the treating surgeons in defining a treatment 
plan according to the aggressiveness of the tumor and 
thus help in preventing the recurrence and increasing 
the survival rate.
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